New Outcomes Data Presented at ICAAC 2014 Further Validates Clinical and Economic Utility of Nanosphere's Verigene Blood Culture Test

NORTHBROOK, Ill., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, announced that data from three outcomes studies demonstrating the clinical and economic impact of the Verigene® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) for rapid sepsis diagnostic testing were presented yesterday at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in Washington, DC this week.

Each of the three outcomes studies presented showed that Verigene BC-GP, when paired with active antimicrobial stewardship program involvement, made a significant impact on patient care. All studies reported a reduction in time to optimal antimicrobial therapy, with two studies reporting an average decrease of over 20 hours. Two of these studies demonstrated an average intensive-care unit (ICU) length-of-stay (LOS) reduction of at least 2.5 days. One study demonstrated a 3 month net cost savings of $153,000 by implementing Verigene BC-GP, leading the authors to forecast a savings of $612,000 for the full year. Settings included two large teaching institutions and a non-teaching community hospital.

"The data presented this week demonstrates the tangible impact Verigene is having on patient outcomes and healthcare costs in hospitals of all sizes," said Michael McGarrity, Nanosphere's president and chief executive officer. "In an era of increasing antimicrobial resistance, the ability of our targeted multiplex tests to facilitate faster and more accurate diagnosis plays an important role in ensuring that clinicians can provide the best possible care to their critically ill patients as quickly as possible."

Studies presented at ICAAC included:

September is Sepsis Awareness Month. Sepsis, a life-threatening disease commonly complicated by antimicrobial resistance, is responsible for 1.6 million hospitalizations and nearly 200,000 deaths per year in the U.S., costing the U.S. healthcare system more than $20 billion per year. Risk of death for sepsis patients increases by 7.6% for each hour appropriate treatment is delayed. As a result, rapid and accurate identification of infection-causing bacteria and their resistance to commonly used antibiotics is the first step toward ensuring that patients receive the right therapy at the right time.

About the Verigene® System

The Verigene System uses Nanosphere's core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene assays target infections of the bloodstream, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company's versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere's customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

CONTACT: Investors: Roger Moody Chief Financial Officer Nanosphere, Inc. 847-400-9021 rmoody@nanosphere.us Michael Rice Founding Partner LifeSci Advisors 646-597-6979 mrice@lifesciadvisors.com Media: Lindsey Saxon Director of Communications Nanosphere, Inc. 847-400-9173 lsaxon@nanosphere.us

Source:Nanosphere, Inc.